CompletedNCT00274677
Lamotrigine or placebo for depression in bipolarity
Placebo comparisonAges 18+United States
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: from 18 years. Other eligibility criteria applied.
- Listed locations
- Burbank and 18 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNovember 2003
- Recruitment status
- Completed
- Enrollment listed in the registry
- 221
- Sponsor
- GlaxoSmithKline
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT00274677
- Official title
Show the full official title
A Multicenter, Double-Blind, Placebo-Controlled, Fixed-Dose, 8-Week Evaluation of the Efficacy and Safety of Lamotrigine in the Treatment of Depression in Patients With Type II Bipolar Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Burbank · Loma Linda · San Diego
16 more locations
- Marietta
- Terre Haute
- Shreveport
- Saint Charles
- Clementon
- Princeton
- New York
- Pleasantville
- Charlotte
- Raleigh
- Beachwood
- Oklahoma City
- Eugene
- Columbia
- Galveston
- Houston
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is GlaxoSmithKline.
Did this study involve medication?
Yes. The study involved medication, including Placebo and lamotrigine.
Who was this study for?
This study was for people with bipolarity. Listed age limits: from 18 years. Other eligibility criteria applied.
